Esther Lu

Medicine & Life Sciences

1. Neoplasms 100%
2. Survival 95%
3. Cancer Survivors 79%
4. Weight Loss 64%
5. Pancreatic Neoplasms 63%
6. Recurrence 58%
7. Pancreaticoduodenectomy 57%
8. Adenocarcinoma 52%
9. Mortality 50%
10. Health 45%
11. Radiotherapy 42%
12. Drug Therapy 42%
13. Breast Neoplasms 42%
14. Squamous Cell Carcinoma of Head and Neck 41%
15. Randomized Controlled Trials 40%
16. Transplants 39%
17. Alzheimer Disease 39%
18. 130-nm albumin-bound paclitaxel 39%
19. Overweight 38%
20. Confidence Intervals 38%
21. Radiosurgery 37%
22. Cetuximab 37%
23. Lung 37%
24. Biomarkers 36%
25. Tissue Donors 35%
26. Prostatic Neoplasms 35%
27. Progression-Free Survival 34%
28. Health Insurance 33%
29. Clinical Trials 31%
30. Costs and Cost Analysis 31%
31. Therapeutics 30%
32. Non-Small Cell Lung Carcinoma 30%
33. Decision Support Techniques 30%
34. Odds Ratio 29%
35. Lymphoma, Large B-Cell, Diffuse 28%
36. Quality of Life 28%
37. Lung Neoplasms 28%
38. Four-Dimensional Computed Tomography 28%
39. Allogeneic Cells 27%
40. Albumin-Bound Paclitaxel 27%
41. Endometrial Neoplasms 26%
42. Neoadjuvant Therapy 26%
43. Implementation Science 26%
44. Diet 25%
45. Tomography 25%
46. gemcitabine 25%
47. Arnold-Chiari Malformation 24%
48. Body Mass Index 24%
49. Comorbidity 24%
50. Uterine Cervical Dysplasia 24%